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Nutritional aspect of pediatric inflammatory 
bowel disease: its clinical importance 
Seung Kim, MD, Hong Koh, MD
Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
Inflammatory bowel disease (IBD) is a chronic inflammatory disease mainly affecting the gastrointestinal 
tract. The incidence of the disease is rapidly increasing worldwide, and a number of patients are diag­
nosed during their childhood or adolescence. Aside from controlling the gastrointestinal symptoms, 
nutritional aspects such as growth, bone mineral density, anemia, micronutrient deficiency, hair loss, 
and diet should also be closely monitored and managed by the pediatric IBD team especially since the 
patients are in the development phase.
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Introduction
Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, is a 
chronic relapsing inflammatory disease mainly affecting the gastrointestinal tract. It is 
believed to develop from an immune reaction that has been triggered by environmental 
factors in genetically susceptible individuals. Incidence of the disease is rapidly increasing 
worldwide and up to 25% of patients are diagnosed during their childhood or adolescence1). 
Although the exact incidence of IBD is not well known, it is also believed to be rapidly 
increasing in Korean children2). Only 4 patients were diagnosed with IBD from 1996–2001 
in a single center study in Korea, while 58 patients were diagnosed with IBD from 2002–
20073). Despite inclusion in the same disease category, IBD in early life appears to manifest 
in a different way compared to adult onset IBD. Since children and adolescents are in the 
process of maturation, this chronic inflammatory disease can adversely affect their growth 
and development. Therefore, additional concerns need to be addressed in pediatric IBD 
patients. In this review, we addressed some points for consideration in the management of 
pediatric IBD, which differs from adult IBD, especially with regards to the nutritional 
involvement.
Differences between pediatric IBD and adult IBD
As extensively studied by Ruel et al.4), there are several differences between pediatric- 
onset and adult- or elderly-onset IBD. With regards to epidemiology, Crohn disease is more 
prevalent than ulcerative colitis in pediatric-onset IBD. This is opposite to the findings in 
adult-onset IBD. Disease location and characteristics also differ between the two age groups. 
In the case of Crohn disease, proximal small bowel involvement and perianal disease are 
more frequent in children than in adults. In ulcerative colitis, extensive pancolitis is 
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predominant in children, while proctitis or left-sided colitis is 
common in adult-onset disease. The natural course of the disease 
also differs according to the age of disease onset. In the case of 
Crohn disease, complications are more prevalent in early-onset 
compared to elderly-onset Crohn disease5) (Fig. 1). Similarly, in 
the case of ulcerative colitis, pediatric-onset disease has a more 
aggressive course compared to adult-onset ulcerative colitis4). The 
cumulative rate of colectomy at 5 years after diagnosis was 20% 
in pediatric ulcerative colitis, and only 8% in elderly-onset ulcera-
tive colitis4). Given that IBD is a lifelong disease, early-onset pati-
ents will suffer for a longer duration and have a higher cumulative 
probability of complications. 
Problems with growth and pubertal development 
The majority of pediatric-onset IBD cases develop around pu-
bertal age, which is a period of growth spurt and sexual develop-
ment. The disease can disturb the normal development of pubertal 
changes, and affect the individual both physically as well as psy-
chologically. Recent systematic reviews have shown that 10%–
56% of Crohn disease and 0%–10% of ulcerative colitis patients 
had growth failure at the time of diagnosis6). One study involving 
Korean pediatric Crohn disease patients reported a 4% growth re-
tardation rate at diagnosis, which is much lower than previous 
western studies. This might be due to ethnic differences, accessi-
bility to gastrointestinal specialists or diagnosis timing in Korea7). 
Up to 46% of children with Crohn disease demonstrated lesser 
height increase before the onset of other symptoms, while only 
12% demonstrated normal height at the time of diagnosis. Con-
versely, children with ulcerative colitis demonstrated a decrease 
in height velocity in only 3%–10% cases8). 
According to a previous summary by Walters et al.9) on the 
pathophysiology of growth impairment in pediatric IBD, chronic 
caloric insufficiency is one of the greatest factors of growth defi-
ciency. Reduced nutrient intake due to disease-related anorexia is 
a major factor and is believed to be related to tumor necrosis 
factor alpha (TNF-α) levels, a major inflammatory cytokine in IBD 
that interacts with the hypothalamic appetite pathway. Further-
more, unlike other nutritional deficiencies, the energy requirement 
for basal metabolism does not exhibit a compensatory reduction 
in IBD patients. Direct cytokines are also involved in this process. 
Insulin-like growth factor-1 is significantly reduced in spite of the 
normal growth hormone (GH) levels. Although the mechanisms 
are unclear, inflammatory cytokines such as TNF-α and interleu-
kin-6 are believed to induce “GH resistance” in IBD patients. A 
frequently used medication for remission induction in IBD, cor-
ticosteroids can also aggravate growth deficiency in various ways. 
It can suppress central GH release and reduce hepatic GH trans-
cription (Table 1). Genetic factors, such as NOD2/CARD15 poly-
morphisms, are believed to be factors of growth impairment9). 
Other problems involving the endocrine system, including a delay 
in pubertal development, are also frequently seen in Crohn disease. 
Previous studies have demonstrated that age at menarche and 
bone age are delayed in Crohn disease patients compared to the 
Table 1. Etiology of growth failure in inflammatory bowel disease
Nutritional aspects
Decreased oral intake due to gastrointestinal symptoms and anorexia
Malabsorption of nutrients
Increased nutritional loss from intestine
Increased energy requirements due to inflammation
Hormonal aspects
Normal GH level and low IGF­1 level (GH resistance due to inflammatory 
cyto kines)
Medication side effect (i.e., corticosteroid)
GH, growth hormone; IGF1, insulin­like growth factor.
Adapted from references8,9).
Fig. 1. The natural course of Inflammatory Bowel Disease accoring to age 
of disease onset. The disease phenotype was recorded according to the 
Montreal classification. CD, Crohn disease; B1, inflammatory phenotype 
without stricture formation and penetrating disease; B2, stricturing dis-
ease; B3, penetrating disease. Adapted from Gower-Rousseau et al. Dig 
Liver Dis 2013;45:89-94, with permission form Elsevier Ltd5).
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control group10,11). 
Although treatment priority remains focused on controlling 
disease activity and nutritional support, endocrinologic treatment, 
including the administration of recombinant human growth hor-
mone, are showing positive preliminary results11,12). 
Decreased bone mineral density & osteoporosis 
Patients with Crohn disease and ulcerative colitis are known to 
be at an increased risk of osteopenia and osteoporosis13,14). Among 
adults with IBD, the prevalence of osteopenia and osteoporosis 
has been reported in 22%–77% and 12%–42% of patients, 
respectively15). One recent study reported that early (before the 
age of 30) disease onset is a risk factor for decreased bone mineral 
density16). In the pediatric population, significant deficits in the 
bone mass have been observed in 10%–40% of pediatric IBD 
patients. These are more prominent in patients with Crohn disease 
compared to those with ulcerative colitis15,17). Among Korean 
children, 20% of those with Crohn disease had bone mineral 
density z scores below –2 standard deviation at diagnosis7). Se-
veral factors are believed to be responsible for the pathogenesis of 
impaired bone mineralization in childhood IBD. These include 
prolonged corticosteroid treatment, low body weight, vitamin D 
deficiency, decreased physical activity, genetic problems, and 
inflammatory cytokines18). According to the North American 
Society for Pediatric Gastroenterology, Hepatology and Nutrition, 
vitamin D status should be checked at least once a year in the 
springtime and supplementation  considered17).
Anemia 
Recent studies have demonstrated that anemia is the most 
common extraintestinal complication of IBD, affecting 19%–25% 
of patients19). Anemia is believed to reflect disease activity, and 
hematocrit levels are included in the pediatric Crohn disease acti-
vity index (PCDAI) score20). Chronic inflammation, as well as iron, 
vitamin B12 and folate deficiencies can cause anemia (Table 2) 
21.22). Among these, iron deficiency anemia dominates more than 
half the cases (57%)23). Different types of IBD medications can 
also give rise to anemia. Iron deficiency is caused by chronic blood 
loss from the gastrointestinal tract as well as inadequate iron ab-
sorption from the duodenum due to mucosal inflammation and/
or rapid bowel transit time. Additionally, ineffective iron utilization 
can also cause functional iron deficiency in IBD patients21). In 
cases of IBD patients with iron deficiency anemia, intravenous 
iron supplementation is the preferred treatment compared to oral 
iron therapy due to better tolerability and higher efficacy24).
Micronutrient deficiency
Patients with IBD are at a risk of micronutrient deficiency of 
vitamins and minerals. Decreased food intake, increased intestinal 
loss, intestinal, hypermetabolic state, drug interaction, and long-
term parenteral nutrition, are believed to be associated with the 
pathogenesis of such deficiencies19). In the case of severe terminal 
ileitis or a history of ileal resection, there is also the risk of vitamin 
B12, folate, and fat-soluble vitamin deficiencies. Folic acid is not 
stored in the human body in large quantities, and even short du-
rations of inadequate intake or malabsorption can cause folate 
deficiency, leading to megaloblastic anemia25). Folic acid deficiency 
can also be caused by sulfasalazine or methotrexate, which are 
inhibitors of dihydrofolate reductase and cellular uptake of folate 
19,26). Iron deficiency is also prevalent because of intestinal bleeding 
and ineffective utilization of stored iron due to proinflammatory 
stimuli. Zinc is an essential micronutrient for humans, and zinc 
deficiency is known to be common in patients with chronic di-
arrhea and malabsorption as well as those in a hypermetabolic 
state19). In one recent study, zinc deficiency was demonstrated in 
40% of IBD subjects and 19% of the control population27). Since 
several micronutrient deficiencies are common in IBD, Hwang et 
al.19) recommend empirical supplementation and careful monito-
ring in special cases. For those undergoing sulfasalazine or metho-
trexate treatment, supplementation with 1 mg/day of folate is 
suggested. Those with significant diarrhea (>300 g/day) will need 
additional intake of magnesium and zinc. Patients with fistulas or 
nonhealing wounds need zinc and vitamin C while those with 
steatorrhea, multiple ileal resections, or severe ileitis require sup-
plementation with fat-soluble vitamins and vitamin B12. Those 
patients on long-term total parenteral nutrition will need supple-
mentation with iron, vitamin D, selenium, zinc, and manganese.
Table 2. Etiology of anemia in inflammatory bowel diseases21,22)
Iron deficiency
Gastrointestinal blood loss
Malabsorption
Anorexia/dietary restrictions
Altered iron metabolism due to inflammatory cytokines
Anemia of chronic disease
Vitamin B12, Folate deficiency
Drug­induced anemia (sulfasalazine, thiopurines)
Hemolysis
Myelodysplastic syndrome
Adapted from references21,22).
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induction30). There is insufficient data on EEN among Korean 
patients. Although Suh et al.31) demonstrated the efficacy of EEN 
in Korean patients with Crohn disease, futher extensive long term 
studies are required. The mechanism of EEN is not exactly 
understood and several hypotheses have been considered. Gut 
rest and reduction of food antigens are believed to be one of these 
mechanisms. EEN is believed to modulate the intestinal microbiota 
in order to render it favorable for the noninflamed intestine. Se-
veral studies have demonstrated reductions in the proinflamma-
tory cytokines and enhanced levels of anti-inflammatory proteins 
in patients treated with EEN32). Although EEN is a safe and effec-
tive treatment option, there is low acceptability due to exclusion 
of a normal diet. Partial enteral nutrition (PEN), which supplies 
liquid nutritional formula in addition to a normal diet, is ineffec-
tive for remission induction. Nevertheless, one report recently 
demonstrated the nutritional and clinical benefits of PEN33) (Fig. 
2). 
Dietary recommendations 
Diet is believed to be a major contributory factor to the de-
velopment and aggravation of gut inflammation through direct 
dietary antigens, alteration of the gut microbiome, and by affecting 
the gastrointestinal permeability34). Even if EEN is not implemented, 
some dietary modifications may induce a positive effect on the 
inflamed bowel. High dietary intake of total fats, PUFAs, omega-6 
fatty acids, and meat are associated with an increased risk of IBD 
Hair loss 
Although the exact prevalence and mechanisms are not well 
known, some patients complain about hair loss throughout the 
course of their disease. Autoimmune response, disease activity, 
malnutrition, micronutrient deficiency (such as zinc), anemia, and 
medications (such as methotrexate, azathioprine, and infliximab) 
are believed to be related to the increasing hair loss in IBD pa-
tients28). Although identification of the cause of hair loss in IBD is 
difficult, correction should be the first step in treating this condi-
tion. Since there are various types of alopecia, a dermatologist 
should be consulted for medical advice, especially in cases of focal 
alopecia, prolonged (6 months) hair loss, and if diagnosis remains 
uncertain29).
Exclusive enteral nutrition 
Exclusive enteral nutrition (EEN) is recognized as an effective 
treatment strategy for pediatric Crohn disease. This therapeutic 
method is accomplished by supplying nutritional liquid formula 
without feeding the normal diet for several weeks. EEN is now 
recognized as a major form of therapy for pediatric Crohn disease 
patients and is recommended as a first line therapy for remission 
Fig. 2. A comparison of the differences (Δ) in nutritional status among patients with severe Crohn 
disease at the initial enrollment and following 1 year of treatment between patients treated with and 
without supportive short-term partial enteral nutrition (SPEN), respectively. *P<0.05. SPEN were per-
formed for 1 month after induction treatment. Micronutrients levels improved in both groups with 
larger increases observed in the SPEN group. Adapted from Kang Y, et al. Gut Liver 2015;9:87-93, 
according to open access policy of Gut and Liver33).
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35). Diets low in fiber and residue are generally recommended for 
patients with Crohn disease in order to prevent bowel obstruction 
and reduce associated symptoms36). However, there is currently 
insufficient evidence of the effectiveness of such dietary modifi-
cations in IBD management. Since dietary habits vary between 
countries, nutritional interventions and dietary recommendations 
should be individualized. 
Conclusions 
The incidence of IBD is rising rapidly, with an increasing ten-
dency for development of the disease among children and adoles-
cents. Since the disease characteristics and natural history differs 
from those of adults, pediatric IBD patients should be considered 
differently, and the nutritional aspects of the disease should be 
prioritized appropriately. 
Conflict of interest
No potential conflict of interest relevant to this article was re-
ported.  
References
 1. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell 
RK, et al. Pediatric modification of the Montreal classification for 
inflammatory bowel disease: the Paris classification. Inflamm 
Bowel Dis 2011;17:1314-21.
 2.  Oh SH, Kim KM. Current issues of pediatric inflammatory bowel 
disease in Korea. Korean J Pediatr 2014;57:465-71.
 3.  Kim BJ, Song SM, Kim KM, Lee YJ, Rhee KW, Jang JY, et al. Cha-
racteristics and trends in the incidence of inflammatory bowel dis-
ease in Korean children: a single-center experience. Dig Dis Sci 
2010;55:1989-95.
 4.  Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD 
across the age spectrum: is it the same disease? Nat Rev Gastroen-
terol Hepatol 2014;11:88-98.
 5.  Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, 
Dauchet L, et al. Epidemiology of inflammatory bowel diseases: 
new insights from a French population-based registry (EPIMAD). 
Dig Liver Dis 2013;45:89-94.
 6.  Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-
onset inflammatory bowel disease: a systematic review. J Clin 
Gastroenterol 2012;46:581-9.
 7.  Song SM, Kim Y, Oh SH, Kim KM. Nutritional status and growth in 
Korean children with Crohn's disease: a single-center study. Gut 
Liver 2014;8:500-7.
 8.  Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, 
Griffiths A. Guidelines for the management of growth failure in 
childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 
14:839-49.
 9.  Walters TD, Griffiths AM. Growth impairment in pediatric inflam-
matory bowel disease. New York: Springer, 2008:109.
 10.  Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric 
patients with Crohn's disease. Dig Dis Sci 2012;57:2975-81.
 11.  DeBoer MD, Denson LA. Delays in puberty, growth, and accrual of 
bone mineral density in pediatric Crohn's disease: despite temporal 
changes in disease severity, the need for monitoring remains. J 
Pediatr 2013;163:17-22.
 12.  Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth 
retardation in paediatric inflammatory bowel disease. Paediatr 
Drugs 2014;16:29-42.
 13.  Targownik LE, Bernstein CN, Leslie WD. Risk factors and manage-
ment of osteoporosis in inflammatory bowel disease. Curr Opin 
Gastroenterol 2014;30:168-74.
 14.  Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. 
Bone mineral density assessment in children with inflammatory 
bowel disease. Gastroenterology 1998;114:902-11.
 15.  Ghishan FK, Kiela PR. Advances in the understanding of mineral 
and bone metabolism in inflammatory bowel diseases. Am J Phy-
siol Gastrointest Liver Physiol 2011;300:G191-201.
 16.  Kim HJ, Hong SJ, Jeon YW, Han JP, Han SH, Kang JH, et al. The 
early onset of disease may be a risk factor for decreased bone mi-
neral density in patients with inflammatory bowel disease. Clin 
Endosc 2013;46:71-6.
 17.  Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, et 
al. Health supervision in the management of children and adoles-
cents with IBD: NASPGHAN recommendations. J Pediatr Gastro-
enterol Nutr 2012;55:93-108.
 18.  Schmidt S, Mellström D, Norjavaara E, Sundh V, Saalman R. Lon-
gitudinal assessment of bone mineral density in children and adole-
scents with inflammatory bowel disease. J Pediatr Gastroenterol 
Nutr 2012;55:511-8.
 19.  Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in 
inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 
2012;18:1961-81.
 20.  Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner 
BS, et al. Development and validation of a pediatric Crohn's disease 
activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
 21.  Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, 
et al. Guidelines on the diagnosis and management of iron defici-
ency and anemia in inflammatory bowel diseases. Inflamm Bowel 
Dis 2007;13:1545-53.
 22.  Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. 
World J Gastroenterol 2009;15:4659-65.
 23.  Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergama-
schi G, et al. Prevalence of anemia in inflammatory bowel diseases 
in european countries: a systematic review and individual patient 
data meta-analysis. Inflamm Bowel Dis 2014;20:936-45.
 24.  Rogler G, Vavricka S. Anemia in inflammatory bowel disease: an 
under-estimated problem? Front Med (Lausanne) 2015;1:58.
 25.  Yakut M, Ustun Y, Kabacam G, Soykan I. Serum vitamin B12 and 
folate status in patients with inflammatory bowel diseases. Eur J 
Intern Med 2010;21:320-3.
 26.  Lindenbaum J. Drugs and vitamin B12 and folate metabolism. Curr 
Concepts Nutr 1983;12:73-87.
 27.  Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin 
and mineral status in patients with inflammatory bowel disease. J 
Pediatr Gastroenterol Nutr 2013;56:89-92.
 28.  Shah R, Abraham B, Hou J, Sellin J. Frequency and associated fac-
tors of hair loss among patients with inflammatory bowel disease. 
World J Gastroenterol 2015;21:229-32.
 29.  Patel KV, Farrant P, Sanderson JD, Irving PM. Hair loss in patients 
with inflammatory bowel disease. Inflamm Bowel Dis 2013;19: 
http://dx.doi.org/10.3345/kjp.2015.58.10.363
Kim S and Koh H • Nutritional aspect of pediatric inflammatory bowel disease
368
1753-63.
 30.  Ruemmele FM, Turner D. Differences in the management of pedia-
tric and adult onset ulcerative colitis: lessons from the joint ECCO 
and ESPGHAN consensus guidelines for the management of pe-
diatric ulcerative colitis. J Crohns Colitis 2014;8:1-4.
 31.  Suh HA, Kim SE, Jang JY, Kim BJ, Kim JS, Lee SY, et al. Efficacy of 
nutritional therapy in children with crohn disease. Korean J Pediatr 
Gastroenterol Nutr 2006;9:210-7.
 32.  Day AS, Burgess L. Exclusive enteral nutrition and induction of 
remission of active Crohn's disease in children. Expert Rev Clin 
Immunol 2013;9:375-83.
 33.  Kang Y, Kim S, Kim SY, Koh H. Effect of short-term partial enteral 
nutrition on the treatment of younger patients with severe Crohn's 
disease. Gut Liver 2015;9:87-93.
 34.  Hou JK, Lee D, Lewis J. Diet and inflammatory bowel disease: re-
view of patient-targeted recommendations. Clin Gastroenterol 
Hepatol 2014;12:1592-600.
 35.  Yamamoto T. Nutrition and diet in inflammatory bowel disease. 
Curr Opin Gastroenterol 2013;29:216-21.
 36.  Lee J, Allen R, Ashley S, Becker S, Cummins P, Gbadamosi A, et al. 
British Dietetic Association evidence-based guidelines for the 
dietary management of Crohn's disease in adults. J Hum Nutr Diet 
2014;27:207-18.
